TrialPath

Find a study

Match me to a study

40 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

38 studies on the map

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleA Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — University of Alabama at Birmingham, BirminghamA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease — Banner Alzheimer?s Institute, PhoenixA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) — Chandler Clinical Trials, LLC, ChandlerA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease — Healthy Brain Clinic, Long BeachA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) — Imaging Endpoints, ScottsdaleA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) — Local Institution - 2609, ChandlerAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Research Site, PhoenixBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) — Fullerton Neurology and Headache Center, FullertonScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies — University of Alabama at Birmingham, BirminghamNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus — Sl0044 50058, AvondaleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus — Research Site, AnnistonPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). — Pinnacle Research Group Llc, AnnistonA Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation — University of Alabama in Birmingham, BirminghamA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). — Banner Alzheimer's Institute, PhoenixA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus — David S Hallegua MD A Professional Corporation, Beverly Hills[18F]PI-2620 Phase 3 Histopathological Study — Barrow Neurological Institute, PhoenixA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixMasupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type — Advanced Research Center, Inc., AnaheimStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixSafety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Esperanza Clinical, MurrietaA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) — Inland Rheumatology Clinical Trials, Inc., UplandA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease — Dermatology Research Associates - 300204025, Los AngelesEffects of Stopping Hydroxychloroquine in Elderly Lupus Disease — University of California, Los Angeles, Los AngelesA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Local Institution - 1227, ChandlerA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) — Gilbert Neurology Partners/CCT Research, GilbertPreventing Alzheimer's With Cognitive Training — University of Florida, GainesvilleA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment — Alloy Clinical Research LLC, KissimmeeEpidemiology and Biomarker Study in Alzheimer's Disease — Care Access - Houston, HoustonVisualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease — Endeavor Health Systems, EvanstonBiomarker Exploration in Aging, Cognition and Neurodegeneration — University of California, Irvine, IrvinePET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 — Perelman Center for Advance Medicine, Philadelphia